

control and new methodologies that can be applied to product characterization and is interested in exploring with the public and industry whether biological/biotechnology pharmaceutical products can be well characterized. FDA intends to develop a definition for well characterized biological/biotechnology pharmaceutical products manufactured using biotechnology.

The goals of this meeting are to: (1) Discuss those analytical techniques, process validations, and parameters that are critical in the characterization of biological/biotechnology pharmaceutical products to assure safety, identity, purity, potency, quality, and consistency; and (2) develop a functional definition for well characterized biological/biotechnology pharmaceutical products. The

information generated at the workshop may be used by FDA in developing future scientific and regulatory policies.

Dated: October 20, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95-26500 Filed 10-24-95; 8:45 am]

BILLING CODE 4160-01-F

Health Resources and Services Administration

Agency Forms Undergoing Paperwork Reduction Act Review

Periodically, the Health Resources and Services Administration (HRSA) publishes a list of information collection requests under review, in compliance with the Paperwork Reduction Act (44

U.S.C. Chapter 35). To request a copy of these documents, call the HRSA Reports Clearance Office on (301)-443-1129.

The following request has been submitted to the Office of Management and Budget for review:

1. Data Collection and Reporting Requirements for Healthy Start—Extension and Revision—Patient records and aggregate data are being collected from Healthy Start grantees in order to evaluate the overall effectiveness of the initiative and the value of specific interventions for varying groups of target women. A number of minor revisions have been proposed based on consultations with grantees regarding availability and utility of the data. Burden estimates are as follows:

Type of report	No. of respondents	Responses per respondent	Average burden per response (hrs)	Total burden hours
Patient Data	15	4	80	4,800
Midyear Reports	15	1	5	75
Aggregate Reports	15	1	40	600

Estimated Total Annual Burden: 5,475 hours.

Written comments and recommendations concerning the proposed information collections should be sent within 30 days of this notice to: Allison Eydtt, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: October 20, 1995.

J. Henry Montes,

Associate Administrator for Policy Coordination.

[FR Doc. 95-26496 Filed 10-24-95; 8:45 am]

BILLING CODE 4160-15-P

National Institutes of Health

National Cancer Institutes; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Cancer Institutes Initial Review Group:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: Subcommittee F—Manpower and Training.

Date: November 8-10, 1995.

Time: 8 a.m.

Place: The Holiday Inn Georgetown, 2101 Wisconsin Ave., N.W., Washington, D.C. 20007.

Contact Person: Mary Bell, Ph.D., 6130 Executive Blvd., Room 611A, Bethesda, MD 20892, Telephone: 301-496-7978.

Committee Name: Subcommittee G—Education.

Date: November 14-15, 1995.

Time: 8 a.m.

Place: The Holiday Inn Georgetown, 2101 Wisconsin Ave., N.W., Washington, D.C. 20007.

Contact Person: Neil B. West, Ph.D., 6130 Executive Blvd., Room 611D, Bethesda, MD 20892, Telephone: 301-402-2785.

Committee Name: Subcommittee C—Basic and Preclinical.

Date: December 4-6, 1995.

Time: December 4-7:30 p.m., December 5-6, 1995, 8 a.m.

Place: Ramada Inn, 8400 Wisconsin Ave., Bethesda, MD 20814.

Contact Person: Virginia Wray, Ph.D., 6130 Executive Plaza, Room 635D, Bethesda, MD 20892, Telephone: 301-496-9236.

Committee Name: Subcommittee B—Comprehensive.

Date: December 7-8, 1995.

Time: 8:30 a.m.

Place: Ramada Inn, 8400 Wisconsin Ave., Bethesda, MD 20814.

Contact Person: Dr. David E. Maslow, 6130 Executive Blvd., Room 643A, Bethesda, MD 20892, (301) 496-2330.

The meetings will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade

secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which could constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control.)

Dated: October 18, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-26384 Filed 10-24-95; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Cancer Institute Special Emphasis Panel (SEP):

Name of SEP: Developmental Therapeutics.

Date: November, 13, 1995.

Time: 9 a.m.

Place: 6130 Executive Blvd., Conference Room F, Rockville, MD 20852.

Contact Person: Lalita Palekar, Ph.D., Scientific Review Administrator, National